RSS | Login | Register

NAPRELAN

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare NAPRELAN to:

Generic Name for NAPRELAN

Naproxen (as sodium) 375mg, 500mg, 750mg; controlled rel tabs.

Legal Classification:

Pharmacological Class for NAPRELAN

NSAID (arylacetic acid deriv.).

Manufacturer of NAPRELAN

Victory Pharma

Indications for NAPRELAN

Mild to moderate pain.

Adult dose for NAPRELAN

1g once daily, or 1.5g once daily for a limited period; max 1g/day thereafter.

Children's dosing for NAPRELAN

Not recommended.

Contraindications for NAPRELAN

Aspirin allergy. 3^rd trimester pregnancy. Coronary artery bypass graft surgery.

Warnings/Precautions for NAPRELAN

Advanced renal disease: not recommended. Active peptic ulcer. History of GI disease. Impaired renal or hepatic function. Heart failure. Edema. Hypertension. Pre-existing asthma. Bleeding disorders. Monitor blood, ocular, and liver function in chronic use. Discontinue if liver dysfunction occurs. Elderly. Debilitated. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions for NAPRELAN

Avoid aspirin. Serum levels increased by probenecid. May potentiate protein-bound drugs (eg, phenytoin, sulfonylureas, sulfonamides). Monitor oral anticoagulants. May antagonize diuretics, antihypertensives. Increased renal toxicity with ACE inhibitors. Methotrexate excretion reduced. Increases lithium levels. Increased risk of GI bleed with alcohol.

Adverse Reactions for NAPRELAN

GI upset, bleeding, or ulceration; headache, flu syndrome, constipation, abdominal pain, dizziness, paresthesias, insomnia, rash (discontinue if occurs), edema, hyperglycemia, arthralgia, myalgia, renal dysfunction, blood dyscrasias, others. See literature re: risk of cardiovascular events.

How is NAPRELAN supplied?

Tabs 375mg—100
500mg—75
750mg—30
Dose card (10-day therapy)—20 (750mg x 6 tabs + 500mg x 14 tabs)

Related Disease:

Pain, general~nonnarcotics

Phase 2 study of SB-509 for diabetic neuropathy (DN)

July 01, 2010

Sangamo BioSciences announced positive Phase 2 data from its ZFP Therapeutic program to develop SB-509 as a treatment for diabetic neuropathy (DN).

McNeil Consumer Healthcare product supply update

June 25, 2010

McNeil Consumer Healthcare announced that it does not anticipate having sources of supply for most of the products that were produced at its Fort Washington, Pennsylvania manufacturing facility before the end of 2010.

Rybix ODT launched for moderate to moderately severe pain

June 18, 2010

Victory Pharma announced that it has launched Rybix ODT (tramadol HCl, orally disintegrating tablets) for the management of moderate to moderately severe pain in patients ≥16 years of age.

McNeil recalls Benadryl Allergy Ultratab and Extra Strength Tylenol Rapid Release Gels

June 16, 2010

McNeil Consumer Healthcare has expanded its January 15, 2010 recall to include four lots of Benadryl Allergy (diphenhydramine) Ultratab Tablets and one lot of Extra Strength Tylenol (acetaminophen) Rapid Release Gels.

CDC issues statement and recommendations regarding prescription drug misuse

June 04, 2010

The CDC announced the 2009 National Youth Risk Behavior Survey (YRBS) found that 1 in 5 high school students have ever taken a prescription drug such as OxyContin (oxycodone, from Purdue), Percocet (oxycodone/acetaminophen, from Endo), Vicodin (hydrocodone/acetaminophen, from Abbott), Adderall (mixed salts of a single-entity amphetamine product, from Shire), Ritalin (methylphenidate, from Novartis), or Xanax (alprazolam, from Pfizer), without a prescription.